Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta

Posted on

In this study, we examined the therapeutic potential of anti-Sclerostin Antibody (Scl-Ab) and bisphosphonate treatments for the bone fragility disorder Osteogenesis Imperfecta (OI). Mice with the Amish OI mutation (Col1a2 G610C mice) and control wild type littermates (WT) were treated from week 5 to week 9 of life with (1) saline (control), (2) zoledronic acid given 0.025 mg/kg s.c. weekly (ZA), (3) Scl-Ab given 50 mg/kg IV weekly (Scl-Ab), or (4) a combination of both (Scl-Ab/ZA). Functional outcomes were prioritized and included bone mineral density (BMD), bone microarchitecture, long bone bending strength, and vertebral compression strength. Read Full study @ Science Direct……

From Science Direct
https://scontent.fbne3-1.fna.fbcdn.net/v/t1.0-9/12143298_1506364219676293_8291450494199083356_n.jpg?oh=8859630f31786799cd1cfd3819c34122&oe=598BC5EA

 

Posted in Research and treatments

Join Us

Osteogenesis imperfecta (OI) is a genetic disorder that causes a person's bones to break easily, often from little or no apparent trauma. OI is also called "brittle bone disease." OI varies in severity from person to person, ranging from a mild type to a severe type that causes death before or shortly after birth.

Become a member Become a sponsor